LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals announced the publication of positive Phase 2 NOVA-1 trial results for LB-102 in JAMA Psychiatry, validating the drug's efficacy and safety profile in acute schizophrenia. The company noted that the ongoing pivotal Phase 3 NOVA-2 trial is on track, with topline data anticipated in the second half of 2027.
Key figures
- Drug Name
- LB-102
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.